APO Research
Talk to an analyst

APO RESEARCH · REPORT

Multi-target MET TKIs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Multi-target MET TKIs Market Outlook and Growth Opportunities 2026

27 December 2025190 pages

Choose your research edition.

Industry ResearchMulti-target MET TKIs Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Multi-target MET TKIs Industry Growth and Trends Forecast to 2032105 pages · $3,450 USDMarket StructureGlobal Multi-target MET TKIs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Multi-target MET TKIs Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Multi-target MET TKIs Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Multi-target MET TKIs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Multi-target MET TKIs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Multi-target MET TKIs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Multi-target MET TKIs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Multi-target MET TKIs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Multi-target MET TKIs market include BDR Pharma, Beacon Pharmaceuticals, Drug International, Elemento Pharma, Everest Pharmaceuticals, Exelixis, Genvio Pharma, MSN Labs and Zydus, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Multi-target MET TKIs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Multi-target MET TKIs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Multi-target MET TKIs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Multi-target MET TKIs market size, projected growth trends, production technologies, key applications, and end-use industries.

Multi-target MET TKIs Segment by Company

BDR Pharma

Beacon Pharmaceuticals

Drug International

Elemento Pharma

Everest Pharmaceuticals

Exelixis

Genvio Pharma

MSN Labs

Zydus

Pfizer

Stada Arzneimittel

Teva

万邦医药

Cipla

Multi-target MET TKIs Segment by Type

Crizotinib

cabozantinib

Other

Multi-target MET TKIs Segment by Application

Medullary Thyroid Cancer

Non-small Cell Lung Cancer

Other

Multi-target MET TKIs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Multi-target MET TKIs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Multi-target MET TKIs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Multi-target MET TKIs significant trends, drivers, influence factors in global and regions.

6. To analyze Multi-target MET TKIs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Multi-target MET TKIs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Multi-target MET TKIs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Multi-target MET TKIs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Multi-target MET TKIs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Multi-target MET TKIs industry.

Chapter 3: Detailed analysis of Multi-target MET TKIs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Multi-target MET TKIs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Multi-target MET TKIs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Multi-target MET TKIs Industry Trends Table 2. Multi-target MET TKIs Industry Drivers Table 3. Multi-target MET TKIs Industry Opportunities and Challenges Table 4. Multi-target MET TKIs Industry Restraints Table 5. Global Multi-target MET TKIs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Multi-target MET TKIs Revenue Share by Company (2021-2026) Table 7. Global Multi-target MET TKIs Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Multi-target MET TKIs Sales Volume Share by Company (2021-2026) Table 9. Global Multi-target MET TKIs Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Multi-target MET TKIs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Multi-target MET TKIs Key Company Manufacturing Base & Headquarters Table 12. Global Multi-target MET TKIs Company, Product Type & Application Table 13. Global Multi-target MET TKIs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Multi-target MET TKIs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Crizotinib Table 18. Significant Companies of cabozantinib Table 19. Significant Companies of Other Table 20. Global Multi-target MET TKIs Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Multi-target MET TKIs Sales Volume by Type (2021-2026) & (K Units) Table 22. Global Multi-target MET TKIs Sales Volume by Type (2027-2032) & (K Units) Table 23. Global Multi-target MET TKIs Sales Volume Share by Type (2021-2026) Table 24. Global Multi-target MET TKIs Sales Volume Share by Type (2027-2032) Table 25. Global Multi-target MET TKIs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Multi-target MET TKIs Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Multi-target MET TKIs Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Multi-target MET TKIs Sales Value Share by Type (2021-2026) Table 29. Global Multi-target MET TKIs Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Medullary Thyroid Cancer Table 31. Significant Companies of Non-small Cell Lung Cancer Table 32. Significant Companies of Other Table 33. Global Multi-target MET TKIs Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Multi-target MET TKIs Sales Volume by Application (2021-2026) & (K Units) Table 35. Global Multi-target MET TKIs Sales Volume by Application (2027-2032) & (K Units) Table 36. Global Multi-target MET TKIs Sales Volume Share by Application (2021-2026) Table 37. Global Multi-target MET TKIs Sales Volume Share by Application (2027-2032) Table 38. Global Multi-target MET TKIs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Multi-target MET TKIs Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Multi-target MET TKIs Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Multi-target MET TKIs Sales Value Share by Application (2021-2026) Table 42. Global Multi-target MET TKIs Sales Value Share by Application (2027-2032) Table 43. Global Multi-target MET TKIs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Multi-target MET TKIs Sales by Region (2021-2026) & (K Units) Table 45. Global Multi-target MET TKIs Sales Market Share by Region (2021-2026) Table 46. Global Multi-target MET TKIs Sales by Region (2027-2032) & (K Units) Table 47. Global Multi-target MET TKIs Sales Market Share by Region (2027-2032) Table 48. Global Multi-target MET TKIs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Multi-target MET TKIs Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Multi-target MET TKIs Sales Value Share by Region (2021-2026) Table 51. Global Multi-target MET TKIs Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Multi-target MET TKIs Sales Value Share by Region (2027-2032) Table 53. Global Multi-target MET TKIs Market Average Price (US$/Unit) by Region (2021-2026) Table 54. Global Multi-target MET TKIs Market Average Price (US$/Unit) by Region (2027-2032) Table 55. Global Multi-target MET TKIs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Global Multi-target MET TKIs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Multi-target MET TKIs Sales by Country (2021-2026) & (K Units) Table 58. Global Multi-target MET TKIs Sales Market Share by Country (2021-2026) Table 59. Global Multi-target MET TKIs Sales by Country (2027-2032) & (K Units) Table 60. Global Multi-target MET TKIs Sales Market Share by Country (2027-2032) Table 61. Global Multi-target MET TKIs Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Multi-target MET TKIs Sales Value Market Share by Country (2021-2026) Table 63. Global Multi-target MET TKIs Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Multi-target MET TKIs Sales Value Market Share by Country (2027-2032) Table 65. BDR Pharma Company Information Table 66. BDR Pharma Business Overview Table 67. BDR Pharma Multi-target MET TKIs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. BDR Pharma Multi-target MET TKIs Product Portfolio Table 69. BDR Pharma Recent Development Table 70. Beacon Pharmaceuticals Company Information Table 71. Beacon Pharmaceuticals Business Overview Table 72. Beacon Pharmaceuticals Multi-target MET TKIs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Beacon Pharmaceuticals Multi-target MET TKIs Product Portfolio Table 74. Beacon Pharmaceuticals Recent Development Table 75. Drug International Company Information Table 76. Drug International Business Overview Table 77. Drug International Multi-target MET TKIs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Drug International Multi-target MET TKIs Product Portfolio Table 79. Drug International Recent Development Table 80. Elemento Pharma Company Information Table 81. Elemento Pharma Business Overview Table 82. Elemento Pharma Multi-target MET TKIs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Elemento Pharma Multi-target MET TKIs Product Portfolio Table 84. Elemento Pharma Recent Development Table 85. Everest Pharmaceuticals Company Information Table 86. Everest Pharmaceuticals Business Overview Table 87. Everest Pharmaceuticals Multi-target MET TKIs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Everest Pharmaceuticals Multi-target MET TKIs Product Portfolio Table 89. Everest Pharmaceuticals Recent Development Table 90. Exelixis Company Information Table 91. Exelixis Business Overview Table 92. Exelixis Multi-target MET TKIs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Exelixis Multi-target MET TKIs Product Portfolio Table 94. Exelixis Recent Development Table 95. Genvio Pharma Company Information Table 96. Genvio Pharma Business Overview Table 97. Genvio Pharma Multi-target MET TKIs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Genvio Pharma Multi-target MET TKIs Product Portfolio Table 99. Genvio Pharma Recent Development Table 100. MSN Labs Company Information Table 101. MSN Labs Business Overview Table 102. MSN Labs Multi-target MET TKIs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. MSN Labs Multi-target MET TKIs Product Portfolio Table 104. MSN Labs Recent Development Table 105. Zydus Company Information Table 106. Zydus Business Overview Table 107. Zydus Multi-target MET TKIs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Zydus Multi-target MET TKIs Product Portfolio Table 109. Zydus Recent Development Table 110. Pfizer Company Information Table 111. Pfizer Business Overview Table 112. Pfizer Multi-target MET TKIs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Pfizer Multi-target MET TKIs Product Portfolio Table 114. Pfizer Recent Development Table 115. Stada Arzneimittel Company Information Table 116. Stada Arzneimittel Business Overview Table 117. Stada Arzneimittel Multi-target MET TKIs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Stada Arzneimittel Multi-target MET TKIs Product Portfolio Table 119. Stada Arzneimittel Recent Development Table 120. Teva Company Information Table 121. Teva Business Overview Table 122. Teva Multi-target MET TKIs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. Teva Multi-target MET TKIs Product Portfolio Table 124. Teva Recent Development Table 125. 万邦医药 Company Information Table 126. 万邦医药 Business Overview Table 127. 万邦医药 Multi-target MET TKIs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 128. 万邦医药 Multi-target MET TKIs Product Portfolio Table 129. 万邦医药 Recent Development Table 130. Cipla Company Information Table 131. Cipla Business Overview Table 132. Cipla Multi-target MET TKIs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 133. Cipla Multi-target MET TKIs Product Portfolio Table 134. Cipla Recent Development Table 135. Key Raw Materials Table 136. Raw Materials Key Suppliers Table 137. Multi-target MET TKIs Distributors List Table 138. Multi-target MET TKIs Customers List Table 139. Research Programs/Design for This Report Table 140. Authors List of This Report Table 141. Secondary Sources Table 142. Primary Sources List of Figures Figure 1. Multi-target MET TKIs Product Image Figure 2. Global Multi-target MET TKIs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Multi-target MET TKIs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Multi-target MET TKIs Sales (2021-2032) & (K Units) Figure 5. Global Multi-target MET TKIs Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Multi-target MET TKIs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Crizotinib Image Figure 10. cabozantinib Image Figure 11. Other Image Figure 12. Global Multi-target MET TKIs Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Multi-target MET TKIs Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Multi-target MET TKIs Sales Volume Share by Type (2021-2032) Figure 15. Global Multi-target MET TKIs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Multi-target MET TKIs Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Multi-target MET TKIs Sales Value Share by Type (2021-2032) Figure 18. Medullary Thyroid Cancer Image Figure 19. Non-small Cell Lung Cancer Image Figure 20. Other Image Figure 21. Global Multi-target MET TKIs Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Multi-target MET TKIs Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Multi-target MET TKIs Sales Volume Share by Application (2021-2032) Figure 24. Global Multi-target MET TKIs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Multi-target MET TKIs Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Multi-target MET TKIs Sales Value Share by Application (2021-2032) Figure 27. Global Multi-target MET TKIs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 28. Global Multi-target MET TKIs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Multi-target MET TKIs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Multi-target MET TKIs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Multi-target MET TKIs Sales Value (2021-2032) & (US$ Million) Figure 32. North America Multi-target MET TKIs Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Multi-target MET TKIs Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Multi-target MET TKIs Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Multi-target MET TKIs Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Multi-target MET TKIs Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Multi-target MET TKIs Sales Value (2021-2032) & (US$ Million) Figure 38. South America Multi-target MET TKIs Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Multi-target MET TKIs Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Multi-target MET TKIs Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Multi-target MET TKIs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Multi-target MET TKIs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Multi-target MET TKIs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Multi-target MET TKIs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Multi-target MET TKIs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Multi-target MET TKIs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Multi-target MET TKIs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Multi-target MET TKIs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Multi-target MET TKIs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Multi-target MET TKIs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Multi-target MET TKIs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Multi-target MET TKIs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Multi-target MET TKIs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Multi-target MET TKIs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Multi-target MET TKIs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Multi-target MET TKIs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Multi-target MET TKIs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Multi-target MET TKIs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Multi-target MET TKIs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Multi-target MET TKIs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Multi-target MET TKIs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Multi-target MET TKIs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Multi-target MET TKIs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Multi-target MET TKIs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Multi-target MET TKIs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Multi-target MET TKIs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Multi-target MET TKIs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Multi-target MET TKIs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Multi-target MET TKIs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Multi-target MET TKIs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Multi-target MET TKIs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Multi-target MET TKIs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Multi-target MET TKIs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Multi-target MET TKIs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Multi-target MET TKIs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Multi-target MET TKIs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Multi-target MET TKIs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Multi-target MET TKIs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Multi-target MET TKIs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Multi-target MET TKIs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Multi-target MET TKIs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Multi-target MET TKIs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Multi-target MET TKIs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Multi-target MET TKIs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Multi-target MET TKIs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Multi-target MET TKIs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Multi-target MET TKIs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Multi-target MET TKIs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Multi-target MET TKIs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Multi-target MET TKIs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Multi-target MET TKIs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Multi-target MET TKIs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Multi-target MET TKIs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Multi-target MET TKIs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Multi-target MET TKIs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Multi-target MET TKIs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Multi-target MET TKIs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Multi-target MET TKIs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Multi-target MET TKIs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Multi-target MET TKIs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Multi-target MET TKIs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Multi-target MET TKIs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Multi-target MET TKIs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Multi-target MET TKIs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Multi-target MET TKIs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Multi-target MET TKIs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Multi-target MET TKIs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Multi-target MET TKIs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Multi-target MET TKIs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Multi-target MET TKIs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Multi-target MET TKIs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Multi-target MET TKIs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Multi-target MET TKIs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Multi-target MET TKIs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Multi-target MET TKIs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Multi-target MET TKIs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Multi-target MET TKIs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Multi-target MET TKIs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Multi-target MET TKIs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Multi-target MET TKIs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Multi-target MET TKIs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Multi-target MET TKIs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Multi-target MET TKIs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Multi-target MET TKIs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Multi-target MET TKIs Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Multi-target MET TKIs Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Crizotinib
  • cabozantinib
  • Other
Applications
  • Medullary Thyroid Cancer
  • Non-small Cell Lung Cancer
  • Other
Companies covered
  • BDR Pharma
  • Beacon Pharmaceuticals
  • Drug International
  • Elemento Pharma
  • Everest Pharmaceuticals
  • Exelixis
  • Genvio Pharma
  • MSN Labs
  • Zydus
  • Pfizer
  • Stada Arzneimittel
  • Teva
  • 万邦医药
  • Cipla

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Multi-target MET TKIs Sales Value (2021-2032)
  4. 1.2.2 Global Multi-target MET TKIs Sales Volume (2021-2032)
  5. 1.2.3 Global Multi-target MET TKIs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Multi-target MET TKIs Market Dynamics
  1. 2.1 Multi-target MET TKIs Industry Trends
  2. 2.2 Multi-target MET TKIs Industry Drivers
  3. 2.3 Multi-target MET TKIs Industry Opportunities and Challenges
  4. 2.4 Multi-target MET TKIs Industry Restraints
3 Multi-target MET TKIs Market by Company
  1. 3.1 Global Multi-target MET TKIs Company Revenue Ranking in 2025
  2. 3.2 Global Multi-target MET TKIs Revenue by Company (2021-2026)
  3. 3.3 Global Multi-target MET TKIs Sales Volume by Company (2021-2026)
  4. 3.4 Global Multi-target MET TKIs Average Price by Company (2021-2026)
  5. 3.5 Global Multi-target MET TKIs Company Ranking (2024-2026)
  6. 3.6 Global Multi-target MET TKIs Company Manufacturing Base and Headquarters
  7. 3.7 Global Multi-target MET TKIs Company Product Type and Application
  8. 3.8 Global Multi-target MET TKIs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Multi-target MET TKIs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Multi-target MET TKIs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Multi-target MET TKIs Market by Type
  1. 4.1 Multi-target MET TKIs Type Introduction
  2. 4.1.1 Crizotinib
  3. 4.1.2 cabozantinib
  4. 4.1.3 Other
  5. 4.2 Global Multi-target MET TKIs Sales Volume by Type
  6. 4.2.1 Global Multi-target MET TKIs Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Multi-target MET TKIs Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Multi-target MET TKIs Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Multi-target MET TKIs Sales Value by Type
  10. 4.3.1 Global Multi-target MET TKIs Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Multi-target MET TKIs Sales Value by Type (2021-2032)
  12. 4.3.3 Global Multi-target MET TKIs Sales Value Share by Type (2021-2032)
5 Multi-target MET TKIs Market by Application
  1. 5.1 Multi-target MET TKIs Application Introduction
  2. 5.1.1 Medullary Thyroid Cancer
  3. 5.1.2 Non-small Cell Lung Cancer
  4. 5.1.3 Other
  5. 5.2 Global Multi-target MET TKIs Sales Volume by Application
  6. 5.2.1 Global Multi-target MET TKIs Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Multi-target MET TKIs Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Multi-target MET TKIs Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Multi-target MET TKIs Sales Value by Application
  10. 5.3.1 Global Multi-target MET TKIs Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Multi-target MET TKIs Sales Value by Application (2021-2032)
  12. 5.3.3 Global Multi-target MET TKIs Sales Value Share by Application (2021-2032)
6 Multi-target MET TKIs Regional Sales and Value Analysis
  1. 6.1 Global Multi-target MET TKIs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Multi-target MET TKIs Sales by Region (2021-2032)
  3. 6.2.1 Global Multi-target MET TKIs Sales by Region: 2021-2026
  4. 6.2.2 Global Multi-target MET TKIs Sales by Region (2027-2032)
  5. 6.3 Global Multi-target MET TKIs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Multi-target MET TKIs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Multi-target MET TKIs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Multi-target MET TKIs Sales Value by Region (2027-2032)
  9. 6.5 Global Multi-target MET TKIs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Multi-target MET TKIs Sales Value (2021-2032)
  12. 6.6.2 North America Multi-target MET TKIs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Multi-target MET TKIs Sales Value (2021-2032)
  15. 6.7.2 Europe Multi-target MET TKIs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Multi-target MET TKIs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Multi-target MET TKIs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Multi-target MET TKIs Sales Value (2021-2032)
  21. 6.9.2 South America Multi-target MET TKIs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Multi-target MET TKIs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Multi-target MET TKIs Sales Value Share by Country, 2025 VS 2032
7 Multi-target MET TKIs Country-level Sales and Value Analysis
  1. 7.1 Global Multi-target MET TKIs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Multi-target MET TKIs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Multi-target MET TKIs Sales by Country (2021-2032)
  4. 7.3.1 Global Multi-target MET TKIs Sales by Country (2021-2026)
  5. 7.3.2 Global Multi-target MET TKIs Sales by Country (2027-2032)
  6. 7.4 Global Multi-target MET TKIs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Multi-target MET TKIs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Multi-target MET TKIs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Multi-target MET TKIs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Multi-target MET TKIs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Multi-target MET TKIs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Multi-target MET TKIs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Multi-target MET TKIs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Multi-target MET TKIs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Multi-target MET TKIs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Multi-target MET TKIs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Multi-target MET TKIs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Multi-target MET TKIs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Multi-target MET TKIs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Multi-target MET TKIs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Multi-target MET TKIs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Multi-target MET TKIs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Multi-target MET TKIs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Multi-target MET TKIs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Multi-target MET TKIs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Multi-target MET TKIs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Multi-target MET TKIs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Multi-target MET TKIs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Multi-target MET TKIs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Multi-target MET TKIs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Multi-target MET TKIs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Multi-target MET TKIs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Multi-target MET TKIs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Multi-target MET TKIs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Multi-target MET TKIs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Multi-target MET TKIs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Multi-target MET TKIs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Multi-target MET TKIs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Multi-target MET TKIs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Multi-target MET TKIs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Multi-target MET TKIs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Multi-target MET TKIs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Multi-target MET TKIs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Multi-target MET TKIs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Multi-target MET TKIs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Multi-target MET TKIs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Multi-target MET TKIs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Multi-target MET TKIs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Multi-target MET TKIs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Multi-target MET TKIs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Multi-target MET TKIs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Multi-target MET TKIs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Multi-target MET TKIs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Multi-target MET TKIs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Multi-target MET TKIs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Multi-target MET TKIs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Multi-target MET TKIs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Multi-target MET TKIs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Multi-target MET TKIs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Multi-target MET TKIs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Multi-target MET TKIs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Multi-target MET TKIs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Multi-target MET TKIs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Multi-target MET TKIs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Multi-target MET TKIs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Multi-target MET TKIs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Multi-target MET TKIs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Multi-target MET TKIs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Multi-target MET TKIs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Multi-target MET TKIs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Multi-target MET TKIs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Multi-target MET TKIs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Multi-target MET TKIs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Multi-target MET TKIs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Multi-target MET TKIs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Multi-target MET TKIs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Multi-target MET TKIs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Multi-target MET TKIs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Multi-target MET TKIs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Multi-target MET TKIs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Multi-target MET TKIs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Multi-target MET TKIs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Multi-target MET TKIs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Multi-target MET TKIs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Multi-target MET TKIs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Multi-target MET TKIs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Multi-target MET TKIs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Multi-target MET TKIs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Multi-target MET TKIs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Multi-target MET TKIs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Multi-target MET TKIs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Multi-target MET TKIs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 BDR Pharma
  2. 8.1.1 BDR Pharma Company Information
  3. 8.1.2 BDR Pharma Business Overview
  4. 8.1.3 BDR Pharma Multi-target MET TKIs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 BDR Pharma Multi-target MET TKIs Product Portfolio
  6. 8.1.5 BDR Pharma Recent Developments
  7. 8.2 Beacon Pharmaceuticals
  8. 8.2.1 Beacon Pharmaceuticals Company Information
  9. 8.2.2 Beacon Pharmaceuticals Business Overview
  10. 8.2.3 Beacon Pharmaceuticals Multi-target MET TKIs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Beacon Pharmaceuticals Multi-target MET TKIs Product Portfolio
  12. 8.2.5 Beacon Pharmaceuticals Recent Developments
  13. 8.3 Drug International
  14. 8.3.1 Drug International Company Information
  15. 8.3.2 Drug International Business Overview
  16. 8.3.3 Drug International Multi-target MET TKIs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Drug International Multi-target MET TKIs Product Portfolio
  18. 8.3.5 Drug International Recent Developments
  19. 8.4 Elemento Pharma
  20. 8.4.1 Elemento Pharma Company Information
  21. 8.4.2 Elemento Pharma Business Overview
  22. 8.4.3 Elemento Pharma Multi-target MET TKIs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Elemento Pharma Multi-target MET TKIs Product Portfolio
  24. 8.4.5 Elemento Pharma Recent Developments
  25. 8.5 Everest Pharmaceuticals
  26. 8.5.1 Everest Pharmaceuticals Company Information
  27. 8.5.2 Everest Pharmaceuticals Business Overview
  28. 8.5.3 Everest Pharmaceuticals Multi-target MET TKIs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Everest Pharmaceuticals Multi-target MET TKIs Product Portfolio
  30. 8.5.5 Everest Pharmaceuticals Recent Developments
  31. 8.6 Exelixis
  32. 8.6.1 Exelixis Company Information
  33. 8.6.2 Exelixis Business Overview
  34. 8.6.3 Exelixis Multi-target MET TKIs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Exelixis Multi-target MET TKIs Product Portfolio
  36. 8.6.5 Exelixis Recent Developments
  37. 8.7 Genvio Pharma
  38. 8.7.1 Genvio Pharma Company Information
  39. 8.7.2 Genvio Pharma Business Overview
  40. 8.7.3 Genvio Pharma Multi-target MET TKIs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Genvio Pharma Multi-target MET TKIs Product Portfolio
  42. 8.7.5 Genvio Pharma Recent Developments
  43. 8.8 MSN Labs
  44. 8.8.1 MSN Labs Company Information
  45. 8.8.2 MSN Labs Business Overview
  46. 8.8.3 MSN Labs Multi-target MET TKIs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 MSN Labs Multi-target MET TKIs Product Portfolio
  48. 8.8.5 MSN Labs Recent Developments
  49. 8.9 Zydus
  50. 8.9.1 Zydus Company Information
  51. 8.9.2 Zydus Business Overview
  52. 8.9.3 Zydus Multi-target MET TKIs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Zydus Multi-target MET TKIs Product Portfolio
  54. 8.9.5 Zydus Recent Developments
  55. 8.10 Pfizer
  56. 8.10.1 Pfizer Company Information
  57. 8.10.2 Pfizer Business Overview
  58. 8.10.3 Pfizer Multi-target MET TKIs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Pfizer Multi-target MET TKIs Product Portfolio
  60. 8.10.5 Pfizer Recent Developments
  61. 8.11 Stada Arzneimittel
  62. 8.11.1 Stada Arzneimittel Company Information
  63. 8.11.2 Stada Arzneimittel Business Overview
  64. 8.11.3 Stada Arzneimittel Multi-target MET TKIs Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Stada Arzneimittel Multi-target MET TKIs Product Portfolio
  66. 8.11.5 Stada Arzneimittel Recent Developments
  67. 8.12 Teva
  68. 8.12.1 Teva Company Information
  69. 8.12.2 Teva Business Overview
  70. 8.12.3 Teva Multi-target MET TKIs Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Teva Multi-target MET TKIs Product Portfolio
  72. 8.12.5 Teva Recent Developments
  73. 8.13 万邦医药
  74. 8.13.1 万邦医药 Company Information
  75. 8.13.2 万邦医药 Business Overview
  76. 8.13.3 万邦医药 Multi-target MET TKIs Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 万邦医药 Multi-target MET TKIs Product Portfolio
  78. 8.13.5 万邦医药 Recent Developments
  79. 8.14 Cipla
  80. 8.14.1 Cipla Company Information
  81. 8.14.2 Cipla Business Overview
  82. 8.14.3 Cipla Multi-target MET TKIs Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Cipla Multi-target MET TKIs Product Portfolio
  84. 8.14.5 Cipla Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Multi-target MET TKIs Value Chain Analysis
  2. 9.1.1 Multi-target MET TKIs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Multi-target MET TKIs Sales Mode & Process
  6. 9.2 Multi-target MET TKIs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Multi-target MET TKIs Distributors
  9. 9.2.3 Multi-target MET TKIs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst